Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
Paula Rodríguez‐Otero, Peter M. Voorhees, Mario Boccadoro, Jacob P. Laubach, Hermann Einsele, Douglas W. Sborov, Meletios A Dimopoulos, Annemiek Broijl, Roberto Mina, Andrew Spencer, Fredrik Schjesvold, Rebecca Silbermann, Francesca Gay, Luciano J. Costa, Aurore Perrot, Yanfang Liu, Jianping Wang, Anna Sitthi-Amorn, Robin Carson, Annelore Cortoos, Saad Z. Usmani, Paul G. Richardson, Philippe Moreau, Pieter Sonneveld, Jonathan L. Kaufman (2025). Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS. , 25(10), DOI: https://doi.org/10.1016/j.clml.2025.04.007.
Article25 days agoVenetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study
Rakesh Popat, Meral Beksaç, Meletios A Dimopoulos, Moshe E. Gatt, Francesca Gay, Jae‐Cheol Jo, Prashant Kapoor, Eirini Katodritou, K. Martin Kortüm, Silvia Ling, Chandramouli Nagarajan, Kenshi Suzuki, Lugui Qiu, Maika Onishi, Grace Ku, Monique Dail, Nabanita Mukherjee, Jeremy A. Ross, Mohamed Badawi, Mary Jean Fusco, Edyta Dobkowska, Emma Arriola, Orlando F. Bueno, Nizar J. Bahlis, Shinsuke Iida, Philippe Moreau, Jason Valent, María‐Victoria Mateos (2025). Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. , 44(3), DOI: https://doi.org/10.1200/jco-25-00924.
Article25 days agoCirculating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.
Mattia D’Agostino, Esperanza Martín‐Sánchez, David Žihala, Ioannis V. Kostopoulos, Juan-José Garcés, Noemí Puig, Giuseppe Bertuglia, Tereza Ševčíková, Tom Cupedo, Mark van Duin, Jonathan J. Keats, Elena Zamagni, Philippe Moreau, Sonja Zweegman, Jill Corre, Mario Boccadoro, Meletios A Dimopoulos, Roman Hájek, Bruno Paiva, Pieter Sonneveld, Annemiek Broijl, Evangelos Terpos, Tomáš Jelı́nek, Jesús F. San Miguel, Francesca Gay, Luca Bertamini (2025). Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-364.
Article25 days agoPrevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network
Grigoris Gerotziafas, Despina Fotiou, Inger S. Nijhof, Cihan Ay, Ramón Lecumberri, Alessandra Laroca, Gordon Cook, Monika Engelhardt, Sonja Zweegman, Michel Delforge, Anthony Maraveyas, Eleftheria Lefkou, Marina Marchetti, Niels W.C.J. van de Donk, Francesca Gay, H Ludwig, Hermann Einsele, Jesús F. San Miguel, Meletios A Dimopoulos, Mario Boccadoro, Pieter Sonneveld, Anna Falanga, Evangelos Terpos (2025). Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network. , 9(8), DOI: https://doi.org/10.1002/hem3.70177.
Article25 days agoIsatuximab for the treatment of multiple myeloma: current clinical advances and future directions
Paul G. Richardson, Elisabeth K. O’Donnell, Peter O’Gorman, Lisa Leypoldt, Jacob P. Laubach, Francesca Gay, Xavier Leleu, Thierry Façon, Philippe Moreau, Meletios A Dimopoulos, Hartmut Goldschmidt, K. Elias, Michèle Cavo, Katja Weisel, Jesús G. Berdeja, Robert Z. Orlowski, Meral Beksaç, Aurore Perrot, Joseph Mıkhael, T. John Martin (2025). Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions. , 34(7-8), DOI: https://doi.org/10.1080/13543784.2025.2532446.
Article25 days ago